Swedish Orphan Biovitrum AB (publ) (SOBI) - Net Assets

Latest as of December 2025: Skr37.72 Billion SEK

Based on the latest financial reports, Swedish Orphan Biovitrum AB (publ) (SOBI) has net assets worth Skr37.72 Billion SEK as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr67.43 Billion) and total liabilities (Skr29.71 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr37.72 Billion
% of Total Assets 55.94%
Annual Growth Rate 14.35%
5-Year Change 62.58%
10-Year Change 604.54%
Growth Volatility 47.89

Swedish Orphan Biovitrum AB (publ) - Net Assets Trend (2002–2025)

This chart illustrates how Swedish Orphan Biovitrum AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Swedish Orphan Biovitrum AB (publ) (2002–2025)

The table below shows the annual net assets of Swedish Orphan Biovitrum AB (publ) from 2002 to 2025.

Year Net Assets Change
2025-12-31 Skr37.72 Billion -6.38%
2024-12-31 Skr40.30 Billion +18.98%
2023-12-31 Skr33.87 Billion +27.68%
2022-12-31 Skr26.52 Billion +14.32%
2021-12-31 Skr23.20 Billion +14.83%
2020-12-31 Skr20.21 Billion +19.35%
2019-12-31 Skr16.93 Billion +87.28%
2018-12-31 Skr9.04 Billion +34.92%
2017-12-31 Skr6.70 Billion +25.14%
2016-12-31 Skr5.35 Billion +14.18%
2015-12-31 Skr4.69 Billion +3.68%
2014-12-31 Skr4.52 Billion -5.17%
2013-12-31 Skr4.77 Billion -1.42%
2012-12-31 Skr4.84 Billion -2.53%
2011-12-31 Skr4.96 Billion +14.30%
2010-12-31 Skr4.34 Billion +220.99%
2009-12-31 Skr1.35 Billion +5.28%
2008-12-31 Skr1.28 Billion -11.55%
2007-12-31 Skr1.45 Billion +5.14%
2006-12-31 Skr1.38 Billion -19.08%
2005-12-31 Skr1.71 Billion -17.73%
2004-12-31 Skr2.08 Billion -0.98%
2003-12-31 Skr2.10 Billion +21.45%
2002-12-31 Skr1.73 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Swedish Orphan Biovitrum AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 2243784500000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings Skr22.40 Billion 59.39%
Common Stock Skr196.00 Million 0.52%
Other Components Skr15.12 Billion 40.09%
Total Equity Skr37.72 Billion 100.00%

Swedish Orphan Biovitrum AB (publ) Competitors by Market Cap

The table below lists competitors of Swedish Orphan Biovitrum AB (publ) ranked by their market capitalization.

Company Market Cap
Bank of Baroda
NSE:BANKBARODA
 		$15.68 Billion
Banco de Credito e Inversiones
SN:BCI
 		$15.69 Billion
AB Volvo (publ)
ST:VOLV-A
 		$15.70 Billion
Nordson Corporation
NASDAQ:NDSN
 		$15.70 Billion
W P Carey Inc
NYSE:WPC
 		$15.64 Billion
Shenwan Hongyuan Group Co Ltd
SHE:000166
 		$15.63 Billion
Sands China Ltd
F:599A
 		$15.62 Billion
Banco de Sabadell S.A
MC:SAB
 		$15.62 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Swedish Orphan Biovitrum AB (publ)'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 40,286,000,000 to 37,717,000,000, a change of -2,569,000,000 (-6.4%).
  • Net income of 478,000,000 contributed positively to equity growth.
  • Share repurchases of 245,000,000 reduced equity.
  • New share issuances of 245,000,000 increased equity.
  • Other comprehensive income decreased equity by 981,000,000.
  • Other factors decreased equity by 2,066,000,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Skr478.00 Million +1.27%
Share Repurchases Skr245.00 Million -0.65%
Share Issuances Skr245.00 Million +0.65%
Other Comprehensive Income Skr-981.00 Million -2.6%
Other Changes Skr-2.07 Billion -5.48%
Total Change Skr- -6.38%

Book Value vs Market Value Analysis

This analysis compares Swedish Orphan Biovitrum AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.88x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 24.84x to 3.88x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2002-12-31 Skr16.95 Skr421.00 x
2003-12-31 Skr20.59 Skr421.00 x
2004-12-31 Skr20.38 Skr421.00 x
2005-12-31 Skr16.77 Skr421.00 x
2006-12-31 Skr12.42 Skr421.00 x
2007-12-31 Skr13.90 Skr421.00 x
2008-12-31 Skr11.48 Skr421.00 x
2009-12-31 Skr23.75 Skr421.00 x
2010-12-31 Skr21.78 Skr421.00 x
2011-12-31 Skr20.50 Skr421.00 x
2012-12-31 Skr18.24 Skr421.00 x
2013-12-31 Skr17.98 Skr421.00 x
2014-12-31 Skr16.99 Skr421.00 x
2015-12-31 Skr17.54 Skr421.00 x
2016-12-31 Skr19.89 Skr421.00 x
2017-12-31 Skr24.82 Skr421.00 x
2018-12-31 Skr33.41 Skr421.00 x
2019-12-31 Skr54.90 Skr421.00 x
2020-12-31 Skr64.84 Skr421.00 x
2021-12-31 Skr74.67 Skr421.00 x
2022-12-31 Skr84.89 Skr421.00 x
2023-12-31 Skr103.90 Skr421.00 x
2024-12-31 Skr116.58 Skr421.00 x
2025-12-31 Skr108.50 Skr421.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Swedish Orphan Biovitrum AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 1.27%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 1.69%
  • • Asset Turnover: 0.42x
  • • Equity Multiplier: 1.79x
  • Recent ROE (1.27%) is below the historical average (5.69%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2002 -2.08% -2.75% 0.65x 1.15x Skr-208.43 Million
2003 17.64% 22.31% 0.70x 1.13x Skr160.12 Million
2004 -1.28% -4.11% 0.27x 1.17x Skr-234.05 Million
2005 10.32% 18.81% 0.34x 1.60x Skr5.45 Million
2006 6.71% 7.72% 0.58x 1.50x Skr-45.51 Million
2007 5.44% 6.29% 0.64x 1.34x Skr-66.30 Million
2008 -26.10% -29.40% 0.44x 2.01x Skr-463.86 Million
2009 2.40% 2.50% 0.46x 2.07x Skr-102.84 Million
2010 -2.40% -5.48% 0.27x 1.63x Skr-538.64 Million
2011 0.36% 0.94% 0.29x 1.35x Skr-478.42 Million
2012 -2.09% -5.25% 0.30x 1.31x Skr-584.68 Million
2013 -1.95% -4.27% 0.33x 1.37x Skr-569.88 Million
2014 -5.92% -10.27% 0.41x 1.41x Skr-720.12 Million
2015 1.46% 2.12% 0.39x 1.77x Skr-400.54 Million
2016 15.11% 15.55% 0.52x 1.86x Skr273.64 Million
2017 17.14% 17.64% 0.60x 1.63x Skr478.56 Million
2018 26.75% 26.46% 0.53x 1.90x Skr1.51 Billion
2019 19.52% 23.19% 0.31x 2.70x Skr1.61 Billion
2020 16.06% 21.26% 0.32x 2.39x Skr1.22 Billion
2021 11.55% 17.25% 0.32x 2.10x Skr358.70 Million
2022 9.95% 14.04% 0.36x 1.98x Skr-14.50 Million
2023 7.11% 10.89% 0.30x 2.19x Skr-977.70 Million
2024 9.64% 14.93% 0.34x 1.87x Skr-143.60 Million
2025 1.27% 1.69% 0.42x 1.79x Skr-3.29 Billion

Industry Comparison

This section compares Swedish Orphan Biovitrum AB (publ)'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $108,908,218
  • Average return on equity (ROE) among peers: -92.32%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Swedish Orphan Biovitrum AB (publ) (SOBI) Skr37.72 Billion -2.08% 0.79x $15.66 Billion
BioGaia AB (publ) (BIOG-B) $508.12 Million 42.29% 0.30x $1.30 Billion
Dicot AB (DICOT) $5.36 Million -592.69% 1.31x $82.08 Million
Enzymatica publ AB (ENZY) $76.61 Million -64.91% 0.64x $72.10 Million
Enorama Pharma AB (ERMA) $17.02 Million -96.01% 1.28x $2.49 Million
Gabather AB (publ) (GABA) $12.79 Million -46.65% 0.06x $945.60K
Klaria Pharma Holding AB (KLAR) $41.13 Million -86.99% 0.77x $28.59 Million
Moberg Pharma AB (publ) (MOB) $434.05 Million -3.74% 0.04x $53.31 Million
Nanexa AB (NANEXA) $70.92 Million -35.11% 0.29x $66.57 Million
Newbury Pharmaceuticals AB (NEWBRY) $49.38 Million -39.35% 0.48x $4.25 Million
Orexo AB (ORX) $-126.30 Million 0.00% 0.00x $78.44 Million

About Swedish Orphan Biovitrum AB (publ)

ST:SOBI Sweden Drug Manufacturers - Specialty & Generic
Market Cap
$15.66 Billion
Skr145.52 Billion SEK
Market Cap Rank
#1416 Global
#18 in Sweden
Share Price
Skr421.00
Change (1 day)
+1.84%
52-Week Range
Skr264.40 - Skr421.00
All Time High
Skr421.00
Categories
Companies in Sweden Drug Manufacturers - Specialty & Generic
About

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with… Read more